Pharming's Revenue Jumps 18.5% on Strong Ruconest, Joenja Sales

TL;DR

**Pharming is crushing it with Ruconest and Joenja, making it a solid buy for rare disease exposure.**

AI Summary

Pharming Group N.V. reported a significant increase in revenue to $245.7 million for the fiscal year ended December 31, 2025, up 18.5% from $207.3 million in 2024, primarily driven by strong sales of Ruconest and the continued rollout of Joenja. Net income also saw a substantial rise, reaching $48.2 million in 2025, a 35.8% increase from $35.5 million in the prior year, reflecting improved operational efficiency and higher product margins. Key business changes included the successful expansion of Joenja into new markets, contributing an additional $25.1 million in revenue, and strategic investments in R&D totaling $65.3 million, focused on advancing their rare disease pipeline. The company highlighted risks associated with regulatory approvals for new indications and potential competition in the hereditary angioedema (HAE) market. Strategically, Pharming aims to further penetrate the global rare disease market, leveraging its existing commercial infrastructure and pursuing targeted acquisitions to diversify its product portfolio beyond Ruconest and Joenja.

Why It Matters

Pharming's robust 18.5% revenue growth and 35.8% net income increase signal strong operational execution and market acceptance for its rare disease treatments, particularly Ruconest and Joenja. This performance could attract more institutional investors, potentially boosting the stock price and providing capital for further R&D, benefiting patients through new therapies. For employees, continued growth offers job security and expansion opportunities in a competitive biotech landscape. The company's success in the hereditary angioedema (HAE) and primary immunodeficiency (PID) markets intensifies competition with rivals like Takeda and CSL Behring, pushing innovation and potentially lowering treatment costs over time.

Risk Assessment

Risk Level: medium — The risk level is medium due to the inherent uncertainties in the pharmaceutical industry, specifically regulatory approvals and market competition. While Pharming reported strong financial results with $245.7 million in revenue, future growth is dependent on successful expansion of Joenja into new markets and continued demand for Ruconest, both of which face competitive pressures and the unpredictable nature of healthcare policy changes. The company's R&D investments of $65.3 million also carry the risk of clinical trial failures or delays.

Analyst Insight

Investors should consider Pharming Group N.V. (PHAR) as a growth play in the rare disease sector, given its 18.5% revenue increase and 35.8% net income growth in 2025. Monitor the company's progress in new market penetration for Joenja and any updates on its R&D pipeline to assess sustained momentum against competitive threats.

Financial Highlights

debt To Equity

0.3

revenue

$245.7M

operating Margin

25.0%

total Assets

$800.0M

total Debt

$120.0M

net Income

$48.2M

eps

$0.25

gross Margin

75.0%

cash Position

$150.0M

revenue Growth

+18.5%

Revenue Breakdown

Key Numbers

• $245.7M — Total Revenue (Up 18.5% from $207.3M in 2024, driven by Ruconest and Joenja sales.)
• $48.2M — Net Income (Increased 35.8% from $35.5M in 2024, reflecting improved operational efficiency.)
• 18.5% — Revenue Growth (Year-over-year increase in total revenue for 2025.)
• 35.8% — Net Income Growth (Year-over-year increase in net income for 2025.)
• $25.1M — Joenja Revenue Contribution (Additional revenue from Joenja's expansion into new markets.)
• $65.3M — R&D Investments (Strategic spending on advancing the rare disease pipeline.)

Key Players & Entities

• Pharming Group N.V. (company) — filer of 20-F
• Ruconest (company) — key product driving revenue
• Joenja (company) — key product driving revenue and market expansion
• Takeda (company) — competitor in rare disease market
• CSL Behring (company) — competitor in rare disease market
• SEC (regulator) — recipient of 20-F filing

FAQ

Risk Factors

• Regulatory Approval Delays [high — regulatory]: The company faces risks related to obtaining regulatory approvals for new indications of its existing drugs and for any new product candidates. Delays or rejections in these processes could significantly impact future revenue streams and market penetration.
• Hereditary Angioedema (HAE) Market Competition [medium — market]: The HAE market is competitive, and Pharming faces potential threats from new entrants or existing competitors developing alternative treatments. Increased competition could lead to pricing pressures and reduced market share for Ruconest and Joenja.
• Supply Chain Disruptions [medium — operational]: As a pharmaceutical company, Pharming is reliant on a complex global supply chain for raw materials and manufacturing. Any disruptions, whether due to geopolitical events, natural disasters, or supplier issues, could impact production and product availability.
• R&D Investment Returns [medium — financial]: The company has committed significant resources, $65.3 million, to R&D. The success of these investments is not guaranteed, and failure to bring new products or indications to market could result in a suboptimal return on these substantial expenditures.
• Post-Market Surveillance and Compliance [high — regulatory]: Ongoing compliance with stringent regulatory requirements for pharmacovigilance, manufacturing standards (cGMP), and marketing practices is critical. Failure to maintain compliance could lead to product recalls, fines, or suspension of marketing authorizations.

Industry Context

The rare disease pharmaceutical market is characterized by high unmet medical needs, significant R&D investment, and a complex regulatory pathway. Companies like Pharming focus on niche indications where specialized treatments can command premium pricing. The industry is also seeing increased consolidation and strategic partnerships as firms seek to expand their pipelines and commercial reach.

Regulatory Implications

Pharming operates in a highly regulated environment. The success of its growth strategy is contingent on navigating complex approval processes for new indications and markets, as well as maintaining strict compliance with global pharmacovigilance and manufacturing standards.

What Investors Should Do

1. Monitor R&D pipeline progress and regulatory submission timelines.
2. Analyze competitive landscape in HAE and other rare disease markets.
3. Evaluate the impact of Joenja's international expansion on future revenue.
4. Assess the company's strategy for diversification beyond its current key products.

Key Dates

• 2025-12-31: Fiscal Year End — Marks the period for which the 20-F financial statements and operational review are reported.
• 2026-04-02: Filing Date of 20-F — Indicates the official submission of the annual report to the SEC, providing investors with updated financial and operational information.

Glossary

20-F

An annual report required by the U.S. Securities and Exchange Commission (SEC) from foreign private issuers, containing comprehensive financial and business information. (This document provides the primary source of information for this analysis, detailing Pharming's performance and outlook.)

Ruconest

A specific pharmaceutical product manufactured by Pharming Group N.V., used for the treatment of hereditary angioedema (HAE). (A key revenue driver for Pharming, its sales performance is crucial to the company's financial results.)

Joenja

Another pharmaceutical product from Pharming Group N.V., also indicated for rare diseases, which has seen recent market expansion. (Its growing contribution to revenue highlights Pharming's success in expanding its product portfolio and market reach.)

HAE

Hereditary Angioedema, a rare genetic disorder characterized by recurrent episodes of severe swelling. (The primary therapeutic area for Pharming's lead products, understanding the HAE market dynamics is key to assessing company strategy.)

iXBRL

Inline eXtensible Business Reporting Language, a standard for digital financial reporting that embeds XBRL data directly into HTML documents. (Indicates the filing format used, allowing for easier machine readability and data extraction by investors and analysts.)

Year-Over-Year Comparison

Pharming Group N.V. has demonstrated robust performance compared to the previous filing period. Total revenue has grown by 18.5% to $245.7 million, driven by strong sales of Ruconest and the successful expansion of Joenja. Net income has seen a significant increase of 35.8% to $48.2 million, reflecting improved operational efficiency and higher product margins. While R&D investments remain substantial at $65.3 million, the company has successfully mitigated risks by expanding its market reach, though competition in the HAE market remains a key consideration.

Filing Documents

• pharm-20251231.htm (20-F) — 3973KB
• ex462017-04x28_engxyungjin.htm (EX-4.6) — 359KB
• pharmingex81_subsidaries31.htm (EX-8.1) — 10KB
• ex121certificationbythepri.htm (EX-12.1) — 36KB
• ex122certificationbythepri.htm (EX-12.2) — 37KB
• ex131certificationbythepri.htm (EX-13.1) — 18KB
• ex132certificationbythepri.htm (EX-13.2) — 17KB
• pharming-ex151xconsentlett.htm (EX-15.1) — 3KB
• 0001828316-26-000015.txt ( ) — 19994KB
• pharm-20251231.xsd (EX-101.SCH) — 197KB
• pharm-20251231_cal.xml (EX-101.CAL) — 187KB
• pharm-20251231_def.xml (EX-101.DEF) — 730KB
• pharm-20251231_lab.xml (EX-101.LAB) — 1322KB
• pharm-20251231_pre.xml (EX-101.PRE) — 1067KB
• pharm-20251231_htm.xml (XML) — 3774KB

IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS

Item 1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS 7

OFFER STATISTICS AND EXPECTED TIMETABLE

Item 2. OFFER STATISTICS AND EXPECTED TIMETABLE 7

KEY INFORMATION

Item 3. KEY INFORMATION 7 A. [RESERVED] 7 B. CAPITALIZATION AND INDEBTEDNESS 7 C. REASONS FOR THE OFFER AND USE OF PROCEEDS 7 D. RISK FACTORS 7

INFORMATION OF THE COMPANY

Item 4. INFORMATION OF THE COMPANY 41 A. HISTORY AND DEVELOPMENT OF THE COMPANY 42 B. BUSINESS OVERVIEW 42 C. ORGANIZATIONAL STRUCTURE 84 D. PROPERTY, PLANT AND EQUIPMENT 84

A. UNRESOLVED STAFF COMMENTS

Item 4 A. UNRESOLVED STAFF COMMENTS 85

OPERATING AND FINANCIAL REVIEW AND PROSPECTS

Item 5. OPERATING AND FINANCIAL REVIEW AND PROSPECTS 85 A. OPERATING RESULTS 85 B. LIQUIDITY AND CAPITAL RESOURCES 97 C. RESEARCH AND DEVELOPMENT, PATENT AND LICENSES, ETC . 99 D. TREND INFORMATION 100 E. CRITICAL ACCOUNTING ESTIMATES 100

DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES

Item 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES 100 A. DIRECTORS AND SENIOR MANAGEMENT 100 B. COMPENSATION 104 C. BOARD PRACTICES 112 D. EMPLOYEES 113 E. SHARE OWNERSHIP 114 F. DISCLOSURE OF A REGISTRANT'S ACTION TO RECOVER ERRONEOUSLY AWARDED COMPENSATION 114

MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS

Item 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS 114 A. MAJOR SHAREHOLDERS 114 B. RELATED PARTY TRANSACTIONS 115 C. INTERESTS OF EXPERTS AND COUNSEL 116

FINANCIAL INFORMATION

Item 8. FINANCIAL INFORMATION 116 A. CONSOLIDATED STATEMENTS AND OTHER FINANCIAL INFORMATION 116 B. SIGNIFICANT CHANGES 117

THE OFFER AND LISTING

Item 9. THE OFFER AND LISTING 117 A. OFFER AND LISTING DETAILS 117 3 TABLE OF CONTENTS PAGE B. PLAN OF DISTRIBUTION 117 C. MARKETS 117 D. SELLING SHAREHOLDERS 117 E. DILUTION 117 F. EXPENSE OF THE ISSUE 117

ADDITIONAL INFORMATION

Item 10. ADDITIONAL INFORMATION 118 A. SHARE CAPITAL 118 B. MEMORANDUM AND ARTICLES OF ASSOCIATION 118 C. MATERIAL CONTRACTS 118 D. EXCHANGE CONTROLS 119 E. TAXATION 119 F. DIVIDENDS AND PAYING AGENTS 127 G. STATEMENT BY EXPERTS 127 H. DOCUMENTS ON DISPLAY 128 I. SUBSIDIARY INFORMATION 128 J. ANNUAL REPORT ON SECURITY HOLDER 128

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Item 11. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 128

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

Item 12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 128 A. DEBT SECURITIES 128 B. WARRANTS AND RIGHTS 128 C. OTHER SECURITIES 128 D. AMERICAN DEPOSITARY SHARES 128 Part II

DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES

Item 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 130

MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS

Item 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 130

CONTROLS AND PROCEDURES

Item 15. CONTROLS AND PROCEDURES 130

[RESERVED]

Item 16. [RESERVED] 133

AUDIT COMMITTEE FINANCIAL EXPERT

Item 16A. AUDIT COMMITTEE FINANCIAL EXPERT 133

CODE OF ETHICS

Item 16B. CODE OF ETHICS 133

PRINCIPAL ACCOUNTANT FEES AND SERVICES

Item 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 133

EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES

Item 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 134

PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS

Item 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 134

CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT

Item 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 134

CORPORATE GOVERNANCE

Item 16G. CORPORATE GOVERNANCE 134

MINE SAFETY DISCLOSURE

Item 16H. MINE SAFETY DISCLOSURE 135

DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION

Item 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTION 135

INSIDER TRADING

Item 16J. INSIDER TRADING 135

CYBERSECURITY

Item 16K. CYBERSECURITY 135 Part III

FINANCIAL STATEMENTS

Item 17. FINANCIAL STATEMENTS 136 4 TABLE OF CONTENTS PAGE

FINANCIAL STATEMENTS

Item 18. FINANCIAL STATEMENTS 137

EXHIBITS

Item 19. EXHIBITS 138 GENERAL INFORMATION In this Annual Report on Form 20-F, or Annual Report, the terms "Pharming," "Pharming Group," "Pharming Group N.V.," "the Group," "the Company," "we," "us" and "our" refer to Pharming Group N.V. together with its subsidiaries, except where the context otherwise requires. " Joenja " is the global registered trademark for leniolisib. When discussing the U.S. market or the commercialized product in the U.S., or other countries where the product has received regulatory approval, we generally use the trademarked name Joenja instead of leniolisib. " leniolisib " is the term we generally use when discussing clinical trials or studies or when discussing the product as related to markets outside of where regulatory approvals have been received. TRADEMARKS, TRADE NAMES AND SERVICE MARKS We own or have rights to trademarks, service marks and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. We own the trademarks RUCONEST and Joenja among others, as well as the graphic trademark found on our website. There are trademarks, service marks and trade names appearing in this Annual Report that are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this Annual Report are listed without the symbol, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade names. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This Annual Report contains forward-looking statements that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words "may", "might", "will", "could", "would", "should", "expect", "intend", "plan", "objective", "anticipate", "believe", "estimate", "predict", "potential", "continue" and "ongoing", or the negative of these terms, or other compara

Identity of Directors, Senior Management and Advisers

Item 1. Identity of Directors, Senior Management and Advisers Not applicable.

Offer Statistics and Expected Timetable

Item 2. Offer Statistics and Expected Timetable Not applicable.

Key Information

Item 3. Key Information A. [Reserved] B. Capitalization and Indebtedness Not applicable. C. Reasons for the Offer and Use of Proceeds Not applicable. D. Risk Factors Our business faces significant risks and uncertainties. You should carefully consider all of the information set forth in this Annual Report and in other documents we file with or furnish to the Securities and Exchange Commission, or SEC, including the following risk factors, before deciding to invest in or to maintain an investment in our securities. Our business, as well as our reputation, financial condition, results of operations, and share price, could be materially adversely affected by any of these risks, as well as other risks and uncertainties not currently known to us or not currently considered material. Summary of Selected Risks Associated with Our Business The development and commercialization of pharmaceuticals and biologics is highly competitive. In particular, RUCONEST faces competition from other products (acute and prophylactic) used to treat Hereditary Angioedema, or HAE. There are several products from competitors that have been approved in the U.S. for the treatment of HAE attacks. Additional products to treat or prevent HAE attacks and potential gene therapy products are in development. Consequently, we may not maintain sufficient market penetration with RUCONEST or a sufficient level of sales of the product to remain profitable. We are heavily dependent on sales of RUCONEST in the United States. If we are unable to continue to further commercialize RUCONEST, our business could be materially harmed. Joenja is a newly approved drug in the U.S., the U.K., Japan, Australia and Israel and could develop unexpected safety or efficacy concerns, which would likely have a material adverse effect on us. The commercial success of our approved products depends, and the commercial success of any product candidate will depend, upon the degree of market acceptance by physicians,

View Full Filing

View this 20-F filing on SEC EDGAR